Guggenheim Taxabl Mncpl Mngd Drtn Trst to Issue Monthly Dividend of $0.13 (NYSE:GBAB)

Share on StockTwits

Guggenheim Taxabl Mncpl Mngd Drtn Trst (NYSE:GBAB) declared a monthly dividend on Wednesday, December 4th, Wall Street Journal reports. Investors of record on Friday, December 13th will be paid a dividend of 0.1257 per share by the investment management company on Tuesday, December 31st. This represents a $1.51 dividend on an annualized basis and a dividend yield of 6.40%. The ex-dividend date of this dividend is Thursday, December 12th.

Shares of GBAB stock traded up $0.06 during trading on Wednesday, reaching $23.56. The company had a trading volume of 55,726 shares, compared to its average volume of 48,242. The firm’s 50 day simple moving average is $23.73 and its two-hundred day simple moving average is $24.02. Guggenheim Taxabl Mncpl Mngd Drtn Trst has a one year low of $21.01 and a one year high of $25.58.

About Guggenheim Taxabl Mncpl Mngd Drtn Trst

Guggenheim Taxable Municipal Managed Duration Trust is a closed ended fixed income mutual fund launched by Guggenheim Partners, LLC. The fund is co-managed by Guggenheim Funds Investment Advisors, LLC and Guggenheim Partners Investment Management, LLC. It invests in fixed income markets of the United States.

Read More: Understanding each part of a balance sheet

Dividend History for Guggenheim Taxabl Mncpl Mngd Drtn Trst (NYSE:GBAB)

Receive News & Ratings for Guggenheim Taxabl Mncpl Mngd Drtn Trst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guggenheim Taxabl Mncpl Mngd Drtn Trst and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

New Oriental Education & Tech Grp  Issues  Earnings Results, Beats Expectations By $0.16 EPS
New Oriental Education & Tech Grp Issues Earnings Results, Beats Expectations By $0.16 EPS
Chunghwa Telecom  Issues FY 2019
Pre-Market Earnings Guidance
Chunghwa Telecom Issues FY 2019 Pre-Market Earnings Guidance
Wedbush Increases MacroGenics  Price Target to $16.00
Wedbush Increases MacroGenics Price Target to $16.00
HC Wainwright Reaffirms “Buy” Rating for Interpace Diagnostics Group
HC Wainwright Reaffirms “Buy” Rating for Interpace Diagnostics Group
Cantor Fitzgerald Reaffirms Overweight Rating for Tivity Health
Cantor Fitzgerald Reaffirms Overweight Rating for Tivity Health
GSX Techedu  Now Covered by Analysts at Goldman Sachs Group
GSX Techedu Now Covered by Analysts at Goldman Sachs Group


 
© 2006-2020 Zolmax.